Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

Zardiw Aug. 31 at 1:02 PM

#DDAmanda alerted on $VVOS before this 72% move. Caught it early again. #DDAmanda Chart Previously flagged: $FNGR $TJGC $NCNA Track the next winner: https://DDAmanda.com

0 · Reply

RiseAboveAll752 Aug. 31 at 11:37 AM

$NCNA

0 · Reply

RiseAboveAll752 Aug. 31 at 11:36 AM

$NCNA what happened here, really?

0 · Reply

Mar_3 Aug. 31 at 12:11 AM

$NCNA $MRNA Moderna (55B market cap) went up 200% off success using Mercks Keytruda for Melanoma… NuCana (3 MILLION market cap) is in a partnership with Merck using Keytruda for Melanoma and has shown positive results in NUC 7738… ticking time bomb for NuCana. The upside is insane at $1.50 a share. Millionaires in the making if a buy out doesn’t happen. But cash run way until 2029 would be foolish to have a buyout now with positive results

0 · Reply

ChickenClaw Aug. 28 at 11:07 PM

$NCNA Can You Imagine The Offers Behind Closed Doors They Are Getting....

0 · Reply

BtD111 Aug. 28 at 8:50 PM

$NCNA haah gross isnt it

0 · Reply

bills7765 Aug. 28 at 8:48 PM

$NCNA almost 1 million in volume!!

2 · Reply

browley Aug. 28 at 8:44 PM

$NCNA I can see that some patents are worthless, but negative value?

1 · Reply

browley Aug. 28 at 8:39 PM

$NCNA I'm in at 1.75 can't lose right?

0 · Reply

RiseAboveAll752 Aug. 28 at 8:33 PM

$NCNA took some at 1.37 just in case

0 · Reply

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-06-01T12:43:48.000Z - 3 months ago

NuCana appoints Ian Webster as CFO

Jun 1, 2026, 8:00 AM EDT - 3 months ago

NuCana Appoints Ian Webster as Chief Financial Officer

May 14, 2026, 4:01 PM EDT - 3 months ago

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 5 months ago

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

2026-01-06T13:16:19.000Z - 8 months ago

NuCana appoints Bruce as COO

Jan 6, 2026, 8:00 AM EST - 8 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

2025-12-10T13:15:35.000Z - 9 months ago

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

2025-12-10T13:05:39.000Z - 9 months ago

NuCana presents data at ESMO on NUC-7738

Dec 10, 2025, 8:00 AM EST - 9 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Nov 13, 2025, 4:01 PM EST - 10 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-05T13:15:29.000Z - 10 months ago

NuCana announces grant of composition-of-matter patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 10 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

2025-10-19T21:10:12.000Z - 11 months ago

NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors

2025-10-14T12:16:01.000Z - 11 months ago

NuCana announces publication of new data for NUC-3373

2025-09-05T12:10:43.000Z - 1 year ago

NuCana compliant with all Nasdaq continued listing criteria

Sep 5, 2025, 8:00 AM EDT - 1 year ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 1 year ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 1 year ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-08-08T23:50:31.000Z - 1 year ago

NuCana PLC (ADR) trading halted, news pending

2025-08-01T20:10:41.000Z - 1 year ago

NuCana announces ADS ratio change

Aug 1, 2025, 4:05 PM EDT - 1 year ago

NuCana Announces ADS Ratio Change

2025-07-21T12:28:02.000Z - 1 year ago

NuCana cancels all outstanding Series A Warrants

Jul 21, 2025, 8:05 AM EDT - 1 year ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 1 year ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

2025-05-06T12:42:54.000Z - 1 year ago

NuCana prices 10.8M ADSs at 64.54c in registered direct offering

2025-04-24T10:21:56.000Z - 1 year ago

NuCana files to sell 16.05M American Depositary Shares

2025-03-20T20:55:23.000Z - 1 year ago

NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)

2025-03-20T20:20:12.000Z - 1 year ago

NuCana Reports Q4 EPS GBP (1) vs. GBP (14)

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

2024-11-25T12:05:13.000Z - 1 year ago

NuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

2024-11-11T12:12:48.000Z - 1 year ago

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 2 years ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 2 years ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 2 years ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 2 years ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 2 years ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Nov 16, 2023, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 3 years ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 3 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 3 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 4 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 4 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 4 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Zardiw Aug. 31 at 1:02 PM

#DDAmanda alerted on $VVOS before this 72% move. Caught it early again. #DDAmanda Chart Previously flagged: $FNGR $TJGC $NCNA Track the next winner: https://DDAmanda.com

0 · Reply

RiseAboveAll752 Aug. 31 at 11:37 AM

$NCNA

0 · Reply

RiseAboveAll752 Aug. 31 at 11:36 AM

$NCNA what happened here, really?

0 · Reply

Mar_3 Aug. 31 at 12:11 AM

0 · Reply

ChickenClaw Aug. 28 at 11:07 PM

$NCNA Can You Imagine The Offers Behind Closed Doors They Are Getting....

0 · Reply

BtD111 Aug. 28 at 8:50 PM

$NCNA haah gross isnt it

0 · Reply

bills7765 Aug. 28 at 8:48 PM

$NCNA almost 1 million in volume!!

2 · Reply

browley Aug. 28 at 8:44 PM

$NCNA I can see that some patents are worthless, but negative value?

1 · Reply

browley Aug. 28 at 8:39 PM

$NCNA I'm in at 1.75 can't lose right?

0 · Reply

RiseAboveAll752 Aug. 28 at 8:33 PM

$NCNA took some at 1.37 just in case

0 · Reply

RiseAboveAll752 Aug. 28 at 8:33 PM

$NCNA so yall didn't like the patent news or what?

0 · Reply

ChickenClaw Aug. 28 at 8:32 PM

$NCNA 😃

1 · Reply

bills7765 Aug. 28 at 8:28 PM

$NCNA wow wth going on???

0 · Reply

singhhunnyhp Aug. 28 at 8:23 PM

$FTFT Move some volume to $NCNA

0 · Reply

Ghostalini Aug. 28 at 8:22 PM

$NCNA We fly up to 1.77 just to get mauled be these despicable naked short degenerates. The ones allowing this to happen are even more loathsome. Absolute swine. I wish there was a way we could obliterate them. I'm fed up with this rigged game bullshit.

2 · Reply

singhhunnyhp Aug. 28 at 8:21 PM

$FTFT Move some volume here $NCNA

0 · Reply

RiseAboveAll752 Aug. 28 at 8:20 PM

$NCNA why down-20%?

0 · Reply

Firefly23 Aug. 28 at 8:17 PM

$NCNA received the patent and others went and bought the wrong stock $NCRA

1 · Reply

ikkydiphoenix Aug. 28 at 8:13 PM

$NCNA they just need to find some brave ones who force them into a short squeeze and you'll see they will change job

0 · Reply

ec017 Aug. 28 at 8:10 PM

$NCNA another patent news destroyed just like $XAIR last night meanwhile FTFT running double for announcing a reverse split. Unreal

1 · Reply

MACnTEEZ Aug. 28 at 8:08 PM

$NCNA these pos shorts are destroying everything and soon the sec will lift the pending rule to delist every stock under 5 mil market cap , when that happens u will have stocks delisting left and right, and soon enough thonging left to trade, they really beed to do something about this shorting shit, they shouldnt be able to drop stocks price like nothing,

0 · Reply

FaithFilledTrader Aug. 28 at 8:02 PM

$NCNA they no longer even have to find shares to borrow they just short stocks

0 · Reply

Market Cap	7.33M
Revenue (ttm)	0.00
Net Income (ttm)	-38.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,018,200
Avg Vol	65,212
Day's Range	N/A - N/A
Shares Out	4.16M
Stochastic %K	71%
Beta	2.25
Analysts	Strong Buy
Price Target	$25.00